ExplainerUpdated 7 min read
BPC-157 capsules and pills: what oral BPC-157 was tested for, and what is missing
BPC-157 capsules and pills rest on rat gut, ligament, and fistula studies. No study has measured how much a capsule absorbs in people, and the two registered oral studies have posted no results.
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
The short answer: oral BPC-157 has real animal data behind it, and almost nothing else. In rat studies, BPC-157 given in drinking water helped heal ligaments, bowel, and fistulas, often as well as the injected form. [3] [4] [5] But no study has measured how much of an oral capsule is absorbed in a person, the one registered human trial of oral tablets never posted results, and capsules or pills sold as research chemicals or supplements are outside any lawful supply chain. [7] [8]
This post covers what the oral and injected forms were actually tested for, the stomach-stability and arginate-salt claims behind the capsule market, and the absorption data that does not exist. It does not give dosing advice; there is no established human dose for BPC-157.
What is oral BPC-157?
BPC-157 is a synthetic chain of 15 amino acids based on a fragment of a protein found in human gastric juice. The research group that discovered it describes it as stable in gastric juice and active when given by mouth as well as by injection. [1] That origin story is the main reason BPC-157 is sold as capsules, tablets, and pills, which most peptides are not: most peptides are broken down by stomach acid and digestive enzymes before they can be absorbed.
In the market, "oral BPC-157" covers several things: capsules of the standard peptide, capsules labeled as the arginate salt, tablets, and more recently gummies. None is an FDA approved product, and none has a published human trial behind it. [7]
Does oral BPC-157 work? What the animal studies used
Most of the oral evidence comes from rats given BPC-157 in their drinking water, usually from the same Zagreb laboratory. The findings are consistent within that literature:
- Ligament. After surgical cutting of the knee's medial collateral ligament, BPC-157 improved functional, biomechanical, and microscopic healing over 90 days whether it was injected, applied as a cream, or given in drinking water. [3]
- Short bowel. In rats with most of the small bowel removed, BPC-157 given by mouth or by injection reversed weight loss and increased villus height and gut wall thickness over 4 weeks. [4]
- Fistula. In a colon-to-skin fistula model, BPC-157 given by injection or in drinking water sped closure of both the colon and skin defects. [5]
The same group's reviews summarize similar oral results for ulcers caused by alcohol and anti-inflammatory drugs, and for colitis. [1] [2] What these studies share is the model: rats drinking dissolved peptide over days or weeks, with outcomes read at autopsy. They show oral activity in rats. They do not show that a human capsule delivers a meaningful amount of peptide, and independent replication outside the originating group is limited. [11]
BPC-157 oral vs injection: what the comparisons show
The head-to-head comparisons that exist are within rat studies, where the oral and injected groups often did about equally well. [3] [4] That is the source of the common claim that "oral works just as well."
The claim does not transfer cleanly to people, for three reasons:
- Route to the target. In a gut injury model, an oral dose reaches the injured tissue directly. For a knee or a shoulder, the peptide would have to survive digestion and be absorbed into the blood first.
- Half-life. In the only formal pharmacokinetic study, in rats and dogs, injected BPC-157 had an elimination half-life under 30 minutes and was quickly broken into small fragments and single amino acids. [6] That study tested intravenous and intramuscular dosing only. It did not measure oral absorption.
- No human numbers. A 2026 review of the drug-development record found that BPC-157's human pharmacokinetics are critically under-characterized, that it lacks basic permeability data, and that no pharmaceutical-grade formulation has been developed or validated. [7]
If you are weighing BPC-157 against the other healing peptide it is usually paired with, our BPC-157 vs TB-500 comparison covers both; neither has human evidence for injury healing.
Is BPC-157 stable in stomach acid?
"Gastric stability" is the core selling point for capsules. The supporting evidence is the discovering group's description of BPC-157 as stable in human gastric juice. [2] A 2026 independent review accepted that BPC-157 shows unusual stability in gastric juice and activity by oral, injected, and topical routes in preclinical work. [7]
Stability is not the same as absorption. A peptide can survive stomach acid and still be poorly absorbed through the intestinal wall, or be broken down by enzymes further along the gut. One research team even engineered lactic acid bacteria as a vehicle to carry BPC-157 to the gut lining, which shows that delivering it by mouth is still treated as an open research problem. [10]
What is BPC-157 arginate salt?
BPC-157 arginate is the arginine salt of the same peptide, marketed as the more stable choice for capsules. Once dissolved, the peptide chain is the same molecule, so it carries the same evidence base: animal only.
We found no peer-reviewed study that compares the arginate salt with the standard form for stability, absorption, or effect, in animals or in people. The 2026 formulation review found no validated formulation of any kind and no formal excipient compatibility studies. [7] Until someone publishes that comparison, "more stable" is a manufacturing claim, not a clinical one.
Has anyone measured oral BPC-157 absorption in people?
No published study has. The closest attempts are registered trials without results:
- Oral tablets in healthy volunteers. A randomized, placebo-controlled phase 1 trial of oral BPC-157 tablets was registered in 2015 to measure safety and pharmacokinetics, with an estimated 42 participants. Its status is listed as unknown and no results have been posted. [8]
- Oral gummies. A single-group study of gummies containing BPC-157 in 40 physically active adults, run by the product's maker, measured inflammation markers and self-reported recovery over 8 weeks. It had no control group and no blinding, and it has not posted results. [9]
Neither can tell you whether a capsule works. The first never reported. The second could not separate the product's effect from placebo, time, or training changes even if it does report.
Are BPC-157 capsules and pills legal?
BPC-157 is not an FDA approved drug in any form. FDA's drug center recommended against listing it on the 503A bulks list and FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, according to HHS's policy (Appendix B). [12] [17] BPC-157 is not on the bulks list, and FDA has proposed no rule. [13] On October 28, 2026, HHS released a draft policy saying it does not intend to take enforcement action against licensed compounding of single-ingredient BPC-157 under strict conditions. Oral is one of the allowed routes, but HHS requires documentation that an oral formulation achieves adequate oral bioavailability in humans, the measurement this post finds missing. The policy is a draft, not an FDA approval, and HHS may revisit it. [16] [17] Our explainer on the HHS peptide policy lists every condition. Track updates on the BPC-157 regulatory timeline, and see the state legal guides for pharmacy board rules.
Capsules and pills sold as research chemicals or supplements are not lawful for human use and are not verified for identity or purity. Contamination and inaccurate content are among the main risks reviewers flag for unregulated peptides. [15] The BPC-157 cost page covers what is known about price. BPC-157 is prohibited at all times for tested athletes, in every form. [14]
Where this leaves oral BPC-157
The oral evidence is animal only, mostly from one laboratory, and strongest for gut injury, where an oral dose meets the tissue directly; the inflammatory bowel disease page grades it that way. For tendon and ligament use, see how it ranks on the tendon injury page. Our guides to what peptide therapy is and how to get peptides prescribed cover how prescribing and compounding work today. The companion posts on BPC-157 human studies and BPC-157 for gut health go deeper on the trial record and the gut literature.
What's actually offered, and what that means for you
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [18] [19] [20]
What that means for you
- A pharmacy that compounds BPC-157 relies on HHS's draft policy, which has strict conditions and which HHS can revisit, so it carries some regulatory risk. Compounding it outside those conditions, such as in a blend or by another route, has no federal basis. [17]
- No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [21]
- State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [22]
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [23] [24]
If you're going ahead anyway
Each step is on the BPC-157 page: check the pharmacy's license, what a legitimate prescription and consult look like, why this is safer than a research-use-only product, and questions to ask. These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [21]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
Pages referenced in this article
- PeptideBPC-157
- ConditionInflammatory bowel disease (Crohn disease and ulcerative colitis)
- ConditionTendon injury and tendinopathy
- ComparisonBPC-157 vs TB-500
- RegulatoryBPC-157 regulatory timeline
- CostBPC-157 cost
- IndexState legal guides
Frequently asked questions
Does oral BPC-157 work?
In rats, BPC-157 given in drinking water helped heal ligament, bowel, and fistula injuries in studies from the group that discovered it. No controlled human study of an oral BPC-157 product has published results, so whether a capsule works in people is unknown. [3] [4] [5] [7]
Is oral BPC-157 as good as injections?
Nobody has compared them in people. Several rat studies found oral and injected BPC-157 both effective in the same model, but rat drinking-water studies do not tell you how much of a human capsule reaches the blood. That has never been measured. [3] [4] [7]
What is BPC-157 arginate?
It is an arginine salt of the same peptide, marketed as more stable for oral use. We found no peer-reviewed study that compares the arginate salt with the standard form for stability, absorption, or effect, in animals or people. [7]
Are BPC-157 capsules legal?
BPC-157 is not an FDA approved drug and is not on the 503A bulks list. HHS's October 2026 draft enforcement policy includes oral BPC-157 among its allowed routes, but only for single-ingredient products compounded under strict conditions, with documentation that the formulation achieves adequate oral bioavailability in humans. No study has yet measured oral absorption in people. Capsules sold as research chemicals are not lawful for human use, and WADA prohibits BPC-157 at all times. [7] [13] [14] [17]
Sources
Numbered citations in the article point to these primary sources. PubMed entries link to the indexed abstract. Evidence grades follow our methodology.
- [1]Sikiric P et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des 2011PubMed 21548867, 2011
- [2]Sikiric P et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem 2012PubMed 22300085, 2012
- [3]Cerovecki T et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res 2010PubMed 20225319, 2010
- [4]Sever M et al. Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats. Dig Dis Sci 2009PubMed 19093208, 2009
- [5]Klicek R et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. J Pharmacol Sci 2008PubMed 18818478, 2008
- [6]He L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol 2022PubMed 36588717, 2022
- [7]Mateescu DM et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics 2026PubMed 42198317, 2026
- [8]ClinicalTrials.gov NCT02637284: Phase I pilot study in healthy volunteers to assess the safety and pharmacokinetics of PCO-02, whose active ingredient is BPC-157 (oral tablets; status unknown, no results posted)2015
- [9]ClinicalTrials.gov NCT07752381: single-group, unmasked study of oral gummies containing BPC-157 on inflammation markers and self-reported recovery (completed, no results posted)2026
- [10]Skrlec K et al. Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities. Appl Microbiol Biotechnol 2018PubMed 30191288, 2018